Literature DB >> 2053810

Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

B Oemar, J Brodehl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2053810      PMCID： PMC1793150          DOI： 10.1136/adc.66.6.751

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  7 in total

1.  Long-term assessment of cyclophosphamide therapy for nephrosis in children.

Authors:  J McDonald; A V Murphy; G C Arneil
Journal:  Lancet       Date:  1974-10-26       Impact factor: 79.321

2.  Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome.

Authors:  J Chiu; K N Drummond
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

3.  Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

Authors:  N Ueda; K Kuno; S Ito
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

4.  Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy.

Authors:  E H Garin; N D Pryor; R S Fennell; G A Richard
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

5.  Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.

Authors:  T M Barratt; A Bercowsky; S G Osofsky; J F Soothill
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

6.  Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide.

Authors:  J S Cameron; C Chantler; C S Ogg; R H White
Journal:  Br Med J       Date:  1974-10-05

7.  The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN).

Authors:  J Brodehl; H P Krohn; J H Ehrich
Journal:  Klin Padiatr       Date:  1982 May-Jun       Impact factor: 1.349
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.